Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21230882 | 0.95 | GPR84 (0.33) | ALDH1A1MAPTL3MBTL1SMN1; SMN2MCL1 | |
| SCHEMBL22649776 | 0.90 | GAA (0.30) | GAA | |
| SCHEMBL22645965 | 0.87 | ALDH1A1 (0.35) | ALDH1A1MAPTKDM4EL3MBTL1GAA | |
| SCHEMBL21842648 | 0.85 | ALDH1A1 (0.35) | ALDH1A1MAPTKDM4EL3MBTL1GAA | |
| SCHEMBL22645839 | 0.85 | ALDH1A1 (0.36) | ALDH1A1MAPTKDM4EL3MBTL1GAA | |
| SCHEMBL21472512 | 0.84 | — | — | |
| SCHEMBL23268308 | 0.84 | SMN1; SMN2 (0.36) | ALDH1A1MAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL21472528 | 0.84 | ALDH1A1 (0.40) | ALDH1A1MAPTKDM4EL3MBTL1GAA | |
| SCHEMBL21472309 | 0.83 | — | — | |
| SCHEMBL24937871 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020227537-A1 | DIFFERENTIALLY EXPRESSED IMMUNE CELL MICRORNAS FOR REGULATION OF PROTEIN EXPRESSION | Modernatx, Inc (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | ALDH1A1 4722/4885MAPT 2204/4885KDM4E 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.